Aroa Biosurgery (ASX:ARX) Change In Receivables : A$0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Change In Receivables?

Aroa Biosurgery's change in receivables for the quarter that ended in Mar. 2024 was A$0.00 Mil. It means Aroa Biosurgery's Accounts Receivable stayed the same from Sep. 2023 to Mar. 2024 .

Aroa Biosurgery's change in receivables for the fiscal year that ended in Mar. 2024 was A$0.00 Mil. It means Aroa Biosurgery's Accounts Receivable stayed the same from Mar. 2023 to Mar. 2024 .

Aroa Biosurgery's Accounts Receivable for the quarter that ended in Mar. 2024 was A$10.50 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Aroa Biosurgery's Days Sales Outstanding for the six months ended in Mar. 2024 was 55.73.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Aroa Biosurgery's liquidation value for the six months ended in Mar. 2024 was A$24.53 Mil.

Aroa Biosurgery Change In Receivables Historical Data

The historical data trend for Aroa Biosurgery's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Change In Receivables Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Aroa Biosurgery Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Aroa Biosurgery (ASX:ARX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Aroa Biosurgery's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	10.5	/	34.382	*	91
=	55.73

2. In Ben Graham's calculation of liquidation value, Aroa Biosurgery's accounts receivable are only considered to be worth 75% of book value:

Aroa Biosurgery's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	27.727	-	14.787	+	0.75 * 10.5	+	0.5 * 7.434
=	24.53

Aroa Biosurgery Change In Receivables Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines